Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Pharma Industry Seeks Cooperation from LDP Lawmakers on Pricing Challenges
October 23, 2019
- Industry to Politicians: Start Vaccine Discussions before Approval to Eliminate Lag Time
October 21, 2019
- Chuikyo OKs Insurance Coverage for Chugai’s Companion Diagnostic to Rozlytrek
October 21, 2019
- 1 Case of Person-to-Person Transmission of Xofluza-Resistant Flu Virus Confirmed in Japan
October 17, 2019
- MHLW Taking Public Comments on Rx-to-OTC for Mosapride
October 17, 2019
- 1st Topical JAK Inhibitor Up for MHLW Panel Review Oct. 25, Ono’s Cachexia Drug Still Shelved
October 15, 2019
- MHLW Orphan Status Dropped for Actemra, Rifampicin
October 15, 2019
- Less than 40% of Public Aware that Antibacterials Are Ineffective Against Common Cold: Govt Survey
October 15, 2019
- Self-Medication Tax Break Not a Clear-Cut System, Needs More Awareness: LDP Lawmakers
October 11, 2019
- Chuikyo Wary about Further Reduction in Generic Entry Prices
October 10, 2019
- Japan Doctor, Pharmacist Groups Oppose Delisting of OTC-Like Drugs: LDP Taskforce
October 10, 2019
- Chuikyo Positive to Add Sakigake Drugs for PMP Coverage, Nudges Industry to Show Counterproposal for Company Criteria
October 10, 2019
- CEFP Discussions on Reform Timeline Update Get Underway
October 10, 2019
- As HIF-PH Inhibitor Debut Looms, MHLW Eyes New Medical Fee Schedule for Renal Anemia
October 10, 2019
- MHLW Kicks Off Discussions to Spur Genomic Medicine for Intractable Diseases
October 9, 2019
- Health Minister Keen on Passage of PMD Law Amendment in Extra Diet Session
October 8, 2019
- As Curtain Rises on Diet, MHLW Aims to Get Amended PMD Bill Enacted in Early November
October 7, 2019
- PMDA Reviewing Safety Risks for Takecab Products and More
October 7, 2019
- MOF Panel Kicks Off FY2020 Budget Debate, Prods Discussions on “Benefits and Burdens”
October 4, 2019
- MHLW Sets Up New Office to Take Reports on Inappropriate Detailing Activities from Healthcare Providers
October 3, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…